Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) has shared an announcement.
Clarity Pharmaceuticals has issued 20,721 fully paid ordinary shares following the exercise of options, without disclosure to investors under the Corporations Act. This strategic move reflects Clarity’s compliance with regulatory requirements and may enhance its market positioning by expanding its shareholder base.
The most recent analyst rating on (AU:CU6) stock is a Buy with a A$8.20 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
More about Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals is a clinical stage radiopharmaceutical company specializing in the development of innovative radiopharmaceuticals. It focuses on targeted copper theranostics using its SAR Technology Platform for treating cancer in both children and adults.
Average Trading Volume: 3,091,715
Technical Sentiment Signal: Buy
Current Market Cap: A$1.66B
For detailed information about CU6 stock, go to TipRanks’ Stock Analysis page.